Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and AustraliaAdriano Lazzarin, Miklos Salgo, Bonaventura Clotet et al.|New England Journal of Medicine|2003Cited by 653
Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV–HCV International PanelVincent Soriano, Jürgen Rockstroh, Mark Sulkowski et al.|AIDS|2002Cited by 443
Discordance Between Cerebral Spinal Fluid and Plasma HIV Replication in Patients with Neurological Symptoms Who Are Receiving Suppressive Antiretroviral TherapyAna Canestri, Christine Katlama|Clinical Infectious Diseases|2010Cited by 404
Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical TrialsMark Nelson, Miklos Salgo, Keikawus Arastéh et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2005Cited by 151
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trialJean‐Michel Molina, Juergen Rockstroh, Bach‐Yen Nguyen et al.|The Lancet HIV|2018Cited by 145